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BACKGROUND AND RATIONALE 
Epidemiology and historical context: 
Tuberculosis (TB) has been a known cause of human suffering for at least 8,000 years 1. It 
presents both as a chronic wasting condition and as a highly lethal epidemic. It thrives on 
poverty, overcrowding, and undernutrition. While TB has been endemic in many populations 
since the advent of agriculture, it rose to global pandemic levels with the industrialization of the 
19th century1· 23· 4. 
Technical advances--such as the tuberculin skin test for diagnosis of latent infection, the 
advent of radiographic diagnosis, and the development of effective pharmacotherapy for 
treatment--raised the hope for disease eradication. Unfortunately, human social organization 
wasn't as adanced. In most of the world poverty and other social ills exacerbate poor individual 
adherence to treatment and governmental failure to support control programs. This allows 
Mycobacterium Tuberculosis (MTB) to develop resistance to treatment and spread uncontrolled. 
The appearance and rapid success of the Human Immunodeficiency Virus (HIV) in the last 30 
years has magnified the TB epidemic accelerating global spread2• 
At present, TB is the leading cause of death from a curable infectious disease in adults5. In 
2005 alone, TB infected 8.8 million people, and killed 1.6 million people. One third of the world's 
population is estimated to be infected with TB 6 7• 
MTB has multiple forms of resistance to drug therapy. Multidrug resistant MTB (MDR-TB} is 
resistant to the two most important first-line drugs, Isoniazid and Rifampin. Extensively drug 
resistant MTB (XDR-TB) emerged in 2006. It is resistant to first- and second-line drugs, and was 
the only MTB infection growing in the United States in 20058 . These varieties threaten TB 
control efforts globally9. 
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While TB remains a major public health threat, the epidemics in the U.S. and globally have 
turned in the last decade. In the U.S., rates of active TB disease and TB mortality are 
declining 10• Rates of MDR-TB declined in 2006 among all cases, rising only among foreign-born 
cases of TB. Globally, the rates of new cases and mortality are stable or declining everywhere 
except sub-Saharan Africa6• 11 . Even in sub-Saharan Africa more high-burden countries are 
reporting to the World Health Organization (WHO) and some national control programs are 
showing a reduced rate of increase in TB. 
The TB pandemic, however, is not yet controlled. Drug resistant MTB varieties continue to 
develop and spread in Africa and Eastern Europe, and the disease frequently crosses 
international borders8• 9" 12" 13. TB and HIV stimulate one another, increasing pressure on the 
fragile health systems in the world's poorest and least-stable countries 11 • If TB is not controlled 
in the current hot-spots a new epidemic of incurable XDR-TB may spread unchecked9· 14 
TB and HIV: 
The HIV epidemic drives the TB epidemic in many parts of the world, especially in sub-
Saharan Africa, where up to 70% of patients with TB are infected with HIV 15. According to the 
Joint United Nations Programme on HIV/AIDS (UNAIDS), 33.2 million adults and children are 
living with HIV or AIDS as of 2007. HIV infection impairs immune function, which dramatically 
increases the risk of developing active TB. Tuberculosis, in turn, may stimulate and activate viral 
replication of HIV. 16· 17• 
HIV weakens the immune system by causing the autolysis of macrophages and T-
lymphocyte helper cells,· the very cells responsible for the immune response to TB. In the 
absence of HIV, these cells "eat" the living mycobacterium and then isolate themselves by 
stimulating granuloma formation, which imprisons the mycobacteria so they do not cause 
disease. Once a person is infected with TB and has undergone this immune reaction he or she 
is said to have latent tuberculosis infection (L TBI). The lifetime risk for such a person to get 
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active TB disease is 10%. Active TB is most likely to occur when the body's immune quarantine 
system fails, usually due to old age or additional diseases. Because HIV attacks the very cells 
responsible for quarantining TB, HIV infection is a major risk factor for development of active 
TB. Among people with L TBI the risk of active TB disease in individuals who also have HIV rises 
from 10% per lifetime to 10% per year18. 
Conversely when MTB bacteria are consumed by an HIV infected macrophage it stimulates 
the viral production of HIV. HIV in the absence of TB can also sit dormant in a host for years. 
The host may go for 1 0 or more years without any symptoms and even without replicating virus. 
MTB exposure to an asymptomatic person with HIV activates both diseases. When MTB infects 
a previously HIV infected cell it activates the HIV genetic code in that cell to begin replicating 
viruses. Macrophages produce cytokines in response to contact with MTB and these cytokines 
increase the activity of HIV virus in nearby cells 18• 
This complex immunological synergy results in progressive rapid immunosuppression and 
active TB disease. This can come either from activation of L TBI or rapid evolution to active TB 
from recent exposure. Persons with L TBI who are infected with HIV have been shown to 
develop active TB in as little as 2 years. Persons with HIV have been shown to get active TB in 
early as 60 days after exposure 18. For these reasons, to ensure optimal treatment, it is important 
to know the HIV status of people infected with TB and the TB status of those infected with HIV. 
Measuring TB status with the TST: 
The most common method for evaluating TB status in asymptomatic people is the 
Tuberculin Skin Test (TST) 2· 19. The TST measures delayed type hypersensitivity skin reaction 
to tuberculin proteins. It is a test of immune response to a purified protein derivative (PPD) of 
non-species specific mycobacterium. The main benefits of the TST are that it is inexpensive, 
well studied, and nurses can be trained to do it without the assistance of a lab. 
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The TST has a number of significant detriments. First, because the test is done in vivo, 
each time someone is tested, he or she is exposed to the tuberculin PPD. With repeated testing 
people can develop an immune response to the test, which causes a false positive resulf0. 
Second, the TST is not specific for MTB because the proteins used in the test are common to 
non-tuberculous mycobacteria and proteins in the Bacillus Calmette-Guerin (BCG) vaccine2• 
Thus it detects lifetime cumulative exposure to all forms of mycobacteria21 • Third, immune 
response to MTB wanes over time if the initial infection is isolated effectively by the immune 
system. Thus in a healthy individual with L TBI there may be a false negative result on the TST. 
Also, people with any immunodeficiency, such as HIV and even those with active TB disease 
may receive false negative results because of reduced immune response. To partially make up 
for these variations the TST is read as positive at 5mm induration in people with HIV rather then 
the normal 10mm. Similarly for people in endemic areas with non-TB mycobacteria and high 
rates of BCG, the recommendation is 15mm for positive6• 22 23. The TST is both non-specific and 
non-sensitive in sub-Saharan Africa where community exposure is very high, non-TB 
mycobacteria and BCG vaccination are common, and many people are immunocompromised 
due to HIV, malnutrition, and other illnesses. 
Health care workers and TB risk: 
Health care workers (HCWs) are at risk of contracting MTB due to frequent or prolonged 
exposure to infectious patients24• In spite of the aforementioned problems the TST is used to 
estimate occupational risk of TB. One method is to use cross sectional data to evaluate the 
number of people with L TBI according to a positive TST in an occupational group vs. the 
general population. According to the Institute of Medicine report edited by Field some studies in 
the U.S. and other high-income and low-prevalence countries using this method reported the 
same or even lower rates of L TBI in HCWs vs. the general population25. HCWs however, are 
younger, healthier, and of a higher socioeconomic status than the general population, which are 
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known confounders not accounted for in these cross sectional evaluations26. In addition to the 
issue of confounding, the cross sectional approach is also problematic because the TST tends 
to measure lifetime cumulative exposure rather than recent exposure2 . Cohort studies use TST 
tests over time to identify those who convert from negative to positive. This process takes a long 
time because the TST should not be repeated frequently. Other studies evaluated TB risk by 
measuring the number of cases of active disease among the populations, but applying the 
results from this method is complicated because active disease can occur many years after TB 
infection, and both the time delay and number of cases is very dependant on the HIV rates in 
the studied populations. 
In 2007 Menzies published a review of TB risk among Health Care workers that included 
published works from 1960 to 2005 in low and middle income countries (LMIC), and from 1990 
to 2005 in high-income countries (HIC)27• It is common to separate HICs from LMICs in any 
discussion of TB because the risks, treatments, and recommendations vary for each group. In 
HICs Menzies Joshi and Pai found that the average prevalence of L TBI for HCWs was 24%. 
Positive status for L TBI in HICs was associated with non-occupational factors related to lifetime 
risk such as low socioeconomic status or foreign birth. The risk of TB attributable to heath care 
work in these settings was only 1.1% [0.2 -12%]. 
In LMICs there was a much higher burden of disease as expected. On average 63% of 
HCWs in LMICs were L TBI positive. The risk of TB attributable to heath care work in these 
settings was 5.8% [0 - 11 %]. In both groups the nosocomial risk was related to both the burden 
of TB in the health setting and the implementation of engineering and administrative TB control 
measures 27• 
Earlier in the year the same authors published the review of only LMICs. In this paper Joshi 
discussed the subgroups of HCWs in greater detail and presented the little data available on the 
effect of TB control measures on the occupational risk of TB26. In LMICs, health care settings 
are crowded and even low-cost strategies to reduce transmission of MTB are seldom 
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implemented. High risk of occupational exposure among these HCWs contributes to a 
prevalence of L TBI ranging from 33 to 79%, and an annual risk of infection ranges from 0.5 to 
14.3%. Because the numbers are so high, the attributable-risk of active TB disease due to 
nosocomial exposure ranges from 25 to 5,361 per 100,000 HCWs per yea~6 • 
These high rates of active TB among HCWs in low- and middle-income countries are 
particularly worrisome and often considered to be HIV-associated6 . The increase of disease 
burden from HIV and TB directly reduces the working life expectancy of health care workers in 
an already severely strained environment 11 . There is great concern about nosocomial risk for 
TB because HCWs have frequent contact with people suffering from other chronic diseases who 
are likely susceptible to TB. HCW who are not protected have the potential to spread the 
disease even more than other groups if they become infectious. 
Prevention and TB Infection Control: 
TB Control strategy varies from country to country depending on national resources and the 
burden of disease. In HICs such as the U.S. and Western Europe there is a low burden of TB. 
People at risk for TB in HICs are identifiable as groups such as HCWs, the homeless, 
immigrants, and others. The goal of TB control for these countries is to prevent and eliminate 
the disease28 . They generally use screening tests for at-risk groups and treat anyone found 
positive for L TBI with preventive therapy to avoid active disease. Since Isoniazid for preventive 
therapy (IPT) is inexpensive and safe, and the number of people with L TBI is small, HICs 
screen with the TST to maximize sensitivity. Engineering and other measures are taken to 
reduce occupational risk. 
In low-income high-burden countries TB control prioritizes reduction of active transmission 
of TB, not prevention29· 30• LMICs rely on identification and treatment of active cases to stop 
transmission. In these settings it is unclear how effective it is to treat someone with IPT because 
that person might be reinfected once therapy is stopped. Also the prevalence of L TBI is so high 
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that treating everyone is not feasible. Tests need to be highly specific to be useful and even 
more so, they need to identify those most likely to be spreading the disease. For this reason, 
LMICs rely on direct investigation of sputum smears for mycobacteria. People with MTB in their 
sputum are most infectious and therefore receive priority treatment. 
Very little is published on the effects of infection-control measures, especially in LMICs. It is 
difficult for policy makers to allocate resources away from the more obvious need to identify and 
treat the most infectious cases and toward preventive interventions. In order to make the 
argument for prevention one must be able to estimate the nosocomial risk of TB to the workers 
and the populations they serve and to demonstrate the reduction of that risk through 
implementation of some or all of the available control measures. 
Prevention and Occupational TB infection Control for Health Care Workers: 
In 1994 the Centers for Disease Control (CDC) established comprehensive infection control 
practices to protect HCWs and prevent TB transmission to the general population in U.S. health 
care settings 31 • This action was taken as a response to increasing rates of nosocomial 
transmission and multiple TB outbreaks in the 1990s1• 25 . The CDC guidelines were not based 
on evidence of effectiveness; instead they were implemented to theoretically address known 
mechanisms of transmission. The guidelines include triage methods, behavioral systems of 
isolation, and regular screening and treatment for L TBI, engineering procedures, such as 
negative pressure rooms and antimicrobial radiation through UV lights, as well as the use of 
personal protective equipment such as respirators and masks. Implementation of these 
recommendations has led to a dramatic decline in the burden of TB among HCWs in the U.S.10• 
In order to find any information on the effects of these or other occupational infection control 
programs we searched medical literature available from Medline and Google Scholar in 
November 2007 for Tuberculosis or TB with combinations of secondary phrases such as health 
worker, infection control, prevention or control. We further used the "cited by" in Google Scholar 
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and PLOS in order to find more recent articles. Results were limited to papers published since 
1995, in which there was an evaluation of the effectiveness of TB control measures on HCWs in 
a health care setting. We found five studies evaluating the impact of infection-control strategies 
on the risk of TB disease among HCWs 32' 36• In three of these studies the investigators 
(Blumberg et al, Yanai et al and Baussano et al.) evaluated reduction in TST conversion at large 
referral hospitals after the full CDC recommendations for TB control (including isolation 
procedures, engineering, protocol measures, and personal protective equipment for HCWs) 
were implemented. Blumburg did a cohort study of house staff in the U.S. before and after 
implementing TB control measures and found that the TST conversion rate dropped to less than 
20% of the baseline value (5.8 down to 1.1 conversions per 100 person years (py)). Yanai et al 
demonstrated a similar benefit in Thai HCWs after implementing full TB control measures (9.3 
down to 2.2 conversions per 100 py) as did Baussano in Italy (2.19% per 100py down to 0.84% 
per 1 OOpy). Roth et al. evaluated TST conversion in four Brazilian hospitals; two implemented 
full CDC recommended TB control measures while the other two had no control measures. The 
rate of conversion was more than twice as high in the hospitals with no control measures. None 
of these attempted to evaluate the effect of specific parts of the overall nosocomial prevention 
guidelines. 
Harries et al. evaluated a less comprehensive intervention. They measured TB indirectly by 
evaluating TB registries before and after limited local guidelines were imposed on hospitals in 
Malawi. The guidelines were only for faster recognition and treatment of smear positive TB 
cases so they were not the same as implementing the TB control guidelines. They found that 
while the goal of the intervention was rapid recognition, the time to recognition and treatment 
was unchanged and there was no difference in the number of HCWs being registered with TB. 
One need not address nosocomial risk as an ali-or-nothing investment. It may be possible 
to compare interventions to estimate the benefits and the costs of practical control measures 
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that could be implemented at different levels of investment. These would range from the 
simplest, such as outdoor waiting rooms and open windows, to more expensive interventions, 
like masks for respiratory isolation or UV lights, to the most intensive interventions, such as 
positive pressure rooms and full CDC guidelines. This would allow Ministries of Health to 
identify which prevention measures are effective enough to complement identification and 
treatment of active cases. This might be done through a cohort study that measures baseline 
and follow up L TBI rates in a cohort of at-risk people (such as HCWs) over time. To improve 
upon TST, an L TBI test for this purpose should be repeatable at shorter intervals and compared 
with the exposure level of each individual. It should be free of interaction with non-TB 
mycobacteria so that it can be accurate in a high-burden setting. It should also be independent 
of BCG vaccination. Ideally, it would be more specific for recent infection than lifetime infection. 
Interferon Gama Release Assays 
A new group of tests for L TBI has recently been developed. These tests measure 
interferon-y production by T-cells in response to in-vitro stimulation of whole blood with MTB 
specific proteins not present in BCG and non-TB mycobacteria. As a group they are known as 
interferon-y release assays (IGRAs)19• 37• 38. Two commercially available FDA-approved IGRAs 
have been studied in recent years and are being compared with TSTs in a variety of settings38-50 
. These are the Quantiferon (QFT) and Elispot tests. The IGRAs avoid some of the problems of 
the TST. They use proteins that do not cross react with response to BCG vaccination or non-TB 
mycobacteria. They are ex-vivo tests and so do not stimulate immunity as the TST can. 
There is no gold standard for evaluating L TBI2• 19• In order to evaluate the IGRAs, studies 
have compared to TST for agreement and made correlation with expected levels of exposure, or 
used active TB disease as a surrogate for L TBI. In a meta-analysis comparing the three tests to 
active TB, the pooled sensitivity of the TST was 70% compared to 76% for the QFT test and 
88% for the Elispot. Pooled specificity of the three tests in populations at low risk for L TBI was 
66% for the TST, 97% for the QFT and 92% for the Elispot43. The results of studies completed 
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to date leave more questions as to the benefits and usefulness of !GRAs for the diagnosis of 
L TBI. For instance the IGRA is less likely to be positive after treatment for TB51 • 52• This could 
represent an accurate evaluation of infection or a change in immune response. IGRA has also 
shown marked variability without treatment and this should be evaluated in longer cohort studies 
of untreated people that will demonstrate risk of disease for those who test IGRA positive. 
To date, only a few published studies have focused on the IGRA in HCWs 52• 42· 48• 53• The 
studies by Neinhaus and Harada are done in high income countries (Germany and Japan) and 
examine the benefits of using an IGRA in place of TST due to its possibly superior specificity for 
people with BCG history. 
Pai studied IGRA in a high risk environment. Working in India, Pai et al documented an 
annual risk of MTB infection of 5% among HCWs, which is more than three-fold the risk in the 
general population. They also observed that some HCWs had reversion of the IGRA on serial 
testing. The authors suggest that transient MTB infections are occurring and can be cleared by 
the immune system, a process which goes undetected with the traditional TST. Alternatively, 
this could represent a high level of variability in the IGRA thus implying reduced accuracy or 
reproducibility. In a study of 10 HCWs from the same cohort who were positive for L TBI and 
treated with Isoniazid, Pai documented changes in the IGRA values that might demonstrate 
reversion with treatment and re-conversions with continued exposure in the health care 
setting51 . 
Corbett studied the IGRA in nursing students in a high risk setting in Harare, Zimbabwe, in 
2006 54 They found an annual conversion rate with TST of 19.3 per 100 person-years in nursing 
students as compared to 6.0 per 100 person-years in other polytechnic students (AR 13.3, RR 
3.2). In recent conference proceedings the same authors revealed preliminary results of a 
comparison of TST to IGRA for evaluating conversion 55• They reported in the same group of 
nursing students a conversion rate by IGRA of 27.6 per 100 person-years vs the 19.3 per 100 
person-years by TST {AR 8.3, RR 1.4 ). Corbett et al. concluded that TST markedly under-
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estimates the TB conversion rate and that the IGRA may be a more accurate method of 
assessing infection. 
Summary 
While TB disease rates are leveling off or declining in most of the world, with one third of 
humanity infected and 1.8 million deaths a year, it remains a major public health problem. The 
main threat to global public health from TB is the continually increasing number of infections and 
increasing resistance to treatment in sub-Saharan Africa. Health care workers are at high risk 
for TB and their loss to the infections of TB and HIV is adding further strain to an already fragile 
health system. Research done thus far on the rate HCWs become infected with TB is limited, 
and the difference in risk among various occupational groups is unclear. Methods of TB control 
and prevention have been effective in wealthy countries and in the few middle income countries 
that have implemented them in limited settings. It remains unclear, however, if these methods 
can protect health care workers in high risk areas. Also unclear is which infection control 
interventions, if any, carry practical benefits that outweigh their costs in high risk areas. It is too 
difficult to evaluate these questions with the common test for L TBI (TST) because the TST is a 
poorly effective test, both non-sensitive and non-specific in the high-risk TB settings of sub-
Saharan Africa. A new test for L TBI is now available, the IGRA. The IGRA has some qualities 
that may make it a better test for evaluating TB exposure in HCWs. 
This pilot study proposes to use an IGRA to estimate the annual risk of newly established 
and transient MTB infections in health care workers employed in a setting with high rates of TB 
and HIV. We will focus on two different groups of HCWs. First we will follow the risks of 
conversion as well as reversion and variability of the IGRA as compared to TST in nurses and 
technicians working in TB clinics. This is an expansion of the study of 10 HCWs done by Joshi 
et al in India. We will use the data to gain a better understanding of the use of the IGRA in high 
risk settings. Second we will evaluate baseline risk of conversion in students whose risk profile 
should parallel the general population at baseline then increase to that of HCWs as they begin 
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working in clinical medicine and have increased patient contact. We aim to use this 
methodology and baseline information to plan future studies to assess the effectiveness of TB 
infection control measures in prospective controlled trials within health care settings in sub-
Saharan Africa. 
SPECIFIC AIMS 
Specific aim 1: Describe the fluctuations in IGRA results over a 1 year period among HCWs 
involved in direct TB care. 
Hypothesis: We will observe distinct patterns of IGRA responses among these HCWs: (1) 
sustained high IGRA responses among HCWs with L TBI at baseline who do not receive lsonizid 
Preventive Therapy (IPT); (2) conversions among HCW with negative IGRA at baseline; and (3) 
reversion of IGRA response among HCW with baseline L TBI who receive I PT. A fourth possible 
pattern is fluctuations of IGRA above and below the recommended threshold for a positive test. 
Each of these patterns is in contrast to null pattern of no change or persistent negative test. 
Rationale: Insight into IGRA responses over time among highly exposed HCW will increase 
our understanding and interpretation of IGRA in this population of continuously highly exposed 
individuals. 
Specific aim 2: Assess the rate of IGRA and TST conversion among medical students and 
nursing staff in a high prevalence area for TB and HIV. Determine the rate of agreement 
between IGRA and TST conversion. 
Hypothesis: The annual IGRA conversion rate will be <:1 0% among those negative at 
baseline, and higher than the TST conversion rate. Agreement between IGRA and TST by 
kappa score will be approximately 80%. 
Rationale: Establishing an accurate annual M. tuberculosis infection rate will allow future 
evaluations of effectiveness of different infection control measures. 
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Specific aim 3: Evaluate knowledge and attitudes among HCWs and medical and nursing 
students towards TB, L TBI, and infection control measures. 
Hypothesis: Students and clinic HCWs will have good knowledge on active TB but 
insufficient knowledge on L TBI and TB infection control measures. 
Rationale: Insight into the current knowledge and attitudes of HCW towards the 
occupational risk of M. tuberculosis infection and TB infection control measures will help guide 
implementation plans for TB infection control in high risk settings. 
Specific Aim 4: Estimate the prevalence of L TBI in both HCWs and medical students. 
Hypothesis: HCWs will have high levels of L TBI (75%). Medical students will have low 
levels (10%). 
Rationale: While prevalence of L TBI has been documented in aggregated groups of HCWs 
it has not been shown for physicians or medical students. Insight into the level of risk of TB 
infection for different segments of the healthcare workforce may influence decisions regarding 
worker protection and disease prevention. 
MATERIALS AND METHODS 
Setting: 
This study takes place in South Africa, which according to the WHO ranks 7th on the list of 
22 high TB burden countries. South Africa reported more than 270,000 new and relapsed TB 
cases in 2006. This is an incidence rate of 600/100,000 population. Successful treatment 
completion rates, recorded in 2004, were 70% with interruption rates of 13% and 7.4% mortality 
with treatment 6. 
The burden of HIV disease affects both the incidence of TB and the mortality. South Africa is 
the country with the largest number of HIV infections in the world. HIV prevalence data estimate 
that 29% of 15 to 24 year old pregnant women are HIV positive in South Africa56. South Africa 
has 0.7% of the world's population but 19% of the world population of people co-infected with 
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TB and HIV. South Africa is beset by TB as well as severe HIV epidemics and is working to 
improve cure rates of active disease to 85% 30• 
Prevention of TB transmission through infection control measures is becoming increasingly 
important to the South African TB strategy. As stated by acting Minister of Health, Mr. Jeff 
Radebe, on World Tuberculosis Day57 , "TB is one of the major health challenges currently 
facing South Africa .... Realizing the challenges, the Department of Health developed the 
National TB Crisis Management plan .... The Plan seeks to improve systems that are necessary 
to support the TB control programme .... We have paid particular attention on strengthening 
infection control precautions at our health facilities in order to reduce possible transmission of 
TB in these facilities. Infection control measures are aimed at reducing direct or indirect contact 
transmission by isolating patients, creating adequate bed floor space and improving ventilation 
in wards." 
Johannesburg is South Africa's largest city; it consists of a diverse population and a 
complex public health system under Gauteng province. There are forty-eight community health 
centers for the treatment of TB as well as an inpatient TB hospital for the treatment of drug 
resistant varieties. Johannesburg boasts a prominent medical school and research center in the 
University of Witwatersrand. In Johannesburg there is both a formidable burden of disease and 
a large number of professionals and resources able to complete this study and use the results 
to develop a more comprehensive study in the future. 
Investigators 
This project was organized and developed at UNC-CH under a grant for students and 
faculty funded by the North Carolina Institute of Occupational Health and Safety to Patrick Keller 
MD in the department of Social Medicine and Annelies Van Rie MD PhD in the department of 
Epidemiology. Co-investigators in South Africa were recruited by Dr Van Rie through prior 
contacts. These are: Charles Feldman MD PhD, Professor and Head of the Division of 
Pulmonology and Deputy Chair of the Department of Medicine for the University of 
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Witwatersrand; Kerrigan McCarthy MBBCh DTM&H FCPath (Micro), consultant microbiologist 
responsible for TB/HIV integration activities with the Reproductive Health and HIV research 
Unit, Department of Obstetrics and Gynecology, University of the Witwatersrand; And Francois 
Venter MD FCP, Clinical Director of the HIV Management Cluster, RHRU, and lecturer at the 
Department of Medicine, University of the Witwatersrand and President of the Southern African 
HIV Clinicians Society. Program design was a collaborative process between all of the co-
investigators. Management of the project in South Africa is being done by Kerrigan McCarthy. 
Study Design: 
This study is a prospective 1-year cohort study of two distinct populations: (1) a cohort of 
health care workers involved in inpatient or outpatient TB care and (2) a cohort of medical 
students beginning their clinical training. 
Study Population: 
Cohort 1: Approximately 50 HCWs involved with inpatient or outpatient TB care in Gauteng 
province. Study sites will be selected among the 48 non-mobile clinics that provide TB care and 
the hospitals that provide inpatient TB care. The study sites are selected based on consultation 
with the South African Ministry of Health and Department of Health for Gauteng province in 
South Africa, and as a convenience sample of sites located near the University of 
Witswatersrand. The actual number of volunteers recruited will depend on financial feasibility of 
the study budget as well as on negotiations for permission with the National and provincial 
health departments as well as individual site managers. 50 is used as a reasonable number that 
can be reached. Below is a list of potential sites: 
Inpatient TB care: SANTA tuberculosis hospital in Soweto, JHB; TB referral clinic at 
Baragwanath Hospital 
Outpatient health centers: Esselen, Jeppe, Yeoville, Urban Health, Joubert Park, and 
Rosettenville, Sandown, Randburg, Parkhurst, Crosby, Claremont, Riverlea Major, 
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Roodepoort, Weltevreden Park, Helderkruin, Davidsonville, Princess Clinic, Zandspruit 
Clinic, Siphumlille, Nokuphila, Bophelong, ltireling, Zola, Klipspruit West, Klispruit West, 
Senaoane, Tshiawelo, Protea South, Tladi, Mofolo South, Jabavu, Eastbank, Fourth 
Avenue Alexandra, St Mary's, Marshalltown, Malvern, Eldorado Park, Elia Mostoaledi, 
Michael Maponia, Orlando East, Noordgesis Clinic, Meadowlands, Diepkloof, Ennerdale 
Ext, Lawley Ext, Lenasia Ext, Lenasia South, Mid Ennerdale. 
Inclusion criteria: 
HCW employed in the selected clinics 
Informed consent 
Exclusion criteria 
Currently receiving treatment for active TB 
Plans to move outside of the Gauteng area in the next 12 months 
Refusal to have blood tested for HIV 
Cohort 2: All students enrolled in the 3'd year in medical school at the University of 
Witwatersrand will be invited to participate. These students are selected because they will be 
making the transition from predominantly classroom teaching to bedside teaching and clinical 
training. Students will conduct part of their training in hospital wards with high risk of 
transmission of M. tuberculosis, including the Emergency and ID wards. We expect a 
participation rate of 70% or 154 students enrolled at baseline. Among these, an estimated 111 
students will be eligible to participate in the follow-up study. 
Inclusion criteria: 
Student enrolled in the 3"' year in medical school or 1st clinical year in nursing school 
Informed consent 
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Exclusion criteria for enrollment at baseline: 
Refusal to have blood tested for HIV 
Currently receiving treatment for active TB 
Exclusion criteria for participation in longitudinal study: 
L TBI at baseline assessment as documented by concordant TST and IGRA test. 
Recruitment and consent procedures: 
Cohort 1: Following approval by the Department of Health, selected clinics will be visited by 
study investigators to inform HCWs about the study and obtain informed consent of those 
interested in participating. Participation is voluntary and the DOH will not be informed which 
HCWs participated and which declined participation. 
Cohort 2: Medical students will be recruited through an announcement at the end of a core 
class by a University of the Witwatersrand faculty member not otherwise involved in the study. A 
study flyer and consent form will be distributed at the end of class to interested students. 
Interested students will be asked to return the completed consent form at the time of a specified 
date. At that time, any questions regarding the study will be answered. The University will not be 
informed which students participated and which students declined participation. 
Study procedures 
TST: The TST will be a single step Mantoux technique using 5 TU PPD RT23. The Mantoux 
procedure is performed by injecting 5 TU of PPD subcutaneously (usually on the ventral 
forearm). The procedure can be done in a single step fashion where the test is placed once and 
the skin is read for reaction 48 - 72 hours later or in a two step fashion where a test is placed a 
second time on those with a negative result. The two step is helpful in populations at low risk for 
TB where sensitivity is to be maximized. In this case the placement of the first test stimulates 
immune activity that has been dormant for the second test. The single step will be used 
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because the two-step procedure loses significant specificity without much gain in sensitivity due 
to the high rates of non-tuberculous mycobacteria and BCG vaccination 58. 
Qua~tiferon Gold In-tube lnterferon-y-release-assay: The QuantiFERON ® -TB Gold assay 
detects cell mediated immunity responses in-vitro to tuberculosis infection by measuring 
interferon-gamma (IFN-y) harvested in plasma from whole blood incubated with the M. 
tuberculosis-specific antigens, ESAT-6 & CFP-10. Five mL of venous blood will be collected and 
heparinized by inverting the tube several times. Aliquots of heparinized whole blood will be 
incubated with ESAT-6, CFP-10, T cell mitogen (PHA) and negative control antigens. Following 
16 to 24 hours incubation, the plasma will be harvested. The amount of IFN-y in the plasma 
samples will be quantified by enzyme-linked immunosorbent assay (ELISA). Results are 
reported in International Units relative to recombinant human IFN-y standard preparation. 
In order to minimize test-related variability, identical protocols will be used for baseline and 
follow-up testing, with previous results masked. All assays will be performed in the National 
Health Laboratory Services, led by Wendy Stevens, who has been involved in over 600 clinical 
research projects and provides laboratory support for several NIH networks (HPTN, ACTG, 
PACTG, and CIPRA). 
H IV test: H IV will be tested by the use of 
rapid tests according to the algorithm 
recommended by DOH and WHO. An HIV 
diagnosis requires two positive HIV tests. The 
blood sample taken at visit 1 is enough to 
perform both tests. 
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FlOW CHART 1. ALGORITHM FOR USE Of RAPID HIV TESTS IN TESTING 
AND COUNSELLING SERVICES 
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Knowledge and attitudes questionnaire (appendix A and B): A self administered 
questionnaire will be used to assess knowledge and attitudes about TB, L TBI and infection 
control. The questionnaire will evaluate knowledge attitudes and beliefs among both cohorts on 
TB transmission, diagnosis and treatment of L TBI, and methods for HCWs to prevent 
nosocomial infection. The questionnaire will also assess TB associated stigma, and feasibility of 
interventions for TB infection control. By understanding the perception of HCWs with respect to 
the most feasible methods of TB infection control, we can prepare future studies of the 
effectiveness of those interventions most acceptable to the local workers. 
Exposure to TB among students (Appendix C): A data collection tool will be used to 
document exposure to TB during work/training. 
Study visits 
Cohort 1: At the first study visit informed consent will be elicited in writing. Participants will 
be administered the TST, receive HIV pretest counseling, and blood will be collected for the 
IGRA and HIV tests. Participants will be informed that knowledge of HIV status is necessary to 
correctly interpret the TST test, and that HIV results will be masked from the investigators by 
separating out identifiable information. Participants will receive a questionnaire to complete (self 
administered) and will be given an appointment for the reading of the TST result 48 to 72 hours 
later. Participants will be encouraged to receive HIV results and posttest counseling at the time 
of their choosing with a qualified councilor. Study staff will return to the clinic 48 to 72 hours later 
(second study visit) to read the TST. At the second study visit staff will collect the completed 
questionnaire and give information about the posttest counseling. Participants will receive an 
appointment for the third study visit, 6 months later. One week prior to the third study visit, the 
participant will be contacted by phone to confirm (or reschedule) the appointment. At the third 
study visit, blood will be collected for IGRA and an appointment for the fourth study visit will be 
given. One week prior to the fourth study visit, the participant will be contacted by phone to 
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confirm (or reschedule) the appointment. At the time of the fourth study visit, blood will be 
collected for JGRA and HIV, a TST will be placed and an appointment 48 to 72 hours later for 
TST reading and posttest counseling will be given. At the time of the fifth study visit, the 
induration of the TST test will be read and posttest counseling will be offered. 
A small incentive of R70 (approximately $1 0) will be given to participants in Cohort 1 at 
each time a blood sample for IGRA is collected (see Figure 1). 
FIGURE 1: Expected participation and results for health workers in TB clinics. 
72 health workers are Results: 
eligible to participate t35- TST and I or IGRA 
22 (30%) are positive 
expected to 
*Those treated with I PT decline 
participation 50 participate; will have decline then 
rebound of IGRA. Those including initial TST, 
not treated will remain HIV and IGRA, follow ~ I · high. Those TST up IGRA at 6 months, 
and final TST, HIV, negative will have high 
IGRA at 12 months fluctuations in IGRA 
*8- HIV positive at 
#-This depends on the number of clinics eligible. baseline including those 
t- Assumed 70% are positive. who are TST and IGRA 
:t: - Estimated based on studies by Pai et al. positive. 
*-Estimated at 16% based on data from Shisana et al. SAMJ 04 
Cohort 2: At the first study visit informed consent will be elicited in writing. Participants will 
receive group pretest HIV counseling. A TST will be administered and blood will be collected for 
IGRA and HIV tests. Participants will be informed that knowledge of HIV status is necessary to 
correctly interpret the TST. Participants will receive a questionnaire to complete (self 
administered) and will be given an appointment for the reading of the TST result 48 to 72 hours 
later. Participants will be encouraged to receive posttest counseling at the time of the second 
study visit. At the time of the second study visit, 48 to 72 hours later study staff will read the 
TST, collect the completed questionnaire and offer posttest counseling. Participants with 
concordant positive TST and JGRA test will be infomned that they are not eligible for 
participation in the follow-up study. Eligible participants will receive an appointment for the third 
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study visit, 6 months later. One week prior to the third study visit, participants will be contacted 
by phone to confirm the appointment. At the time of the third study visit, blood will be collected 
for IGRA and an appointment for the fourth study visit will be given. One week prior to the fourth 
study visit, participants will be contacted by phone to confirm the appointment. At the time of the 
fourth study visit, blood will be collected for IGRA and HIV, a TST will be placed and an 
appointment 48 to 72 hours later for TST reading and posttest counseling will be given. At the 
time of the fifth study visit, the induration of the TST will be read and posttest counseling will be 
offered (see Figure 2). 
I FIGURE 2: Expected participation and results for medical students. 
220 students Results: 
66 (30%) eligible to '21 -IGRA 
likely to participate conversion 
decline 
'15- TST participation ... conversion 154 will get 
initial TST, HIV, 
.. *15 - HIV positive IGRA 
t43 (28%) at baseline including those 
ineligible ... who are TST and 
TST+ and 111 will get follow up IGRA positive. 
IGRA+ IGRA at 6 months 
and final TST, HIV, Unknown- HIV 
IGRA at 12 months conversion rate 
t · Estimated based on the data from Corbett et al. 
+-Estimated IGRA and TST conversion rates 19% and 14% by averaging the data 
from Corbett et al. and Pai et al. 
*-Estimated at 14% HIV pas. among nursing students, Cornelly SAMJ 07, 8% among 
medical students 
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All study visits will .be organized in groups. At each study visit, a 
small lunch will be provided to participants. 
Care and treatment for participants with identified L TBI or HIV infection 
L TBI and Preventive Therapy: 
Currently, the South African department of Health only recommends TST-based screening 
for L TBI for children under 5 years of age in contact with an infectious adult case of TB and 
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among people living with HIV because of the high risk of active TB in these populations30• This 
is in line with WHO recommendations22• 29• There is no policy regarding screening and treatment 
for L TBI among HCWs. IGRA tests are available in South Africa, but test results are only used 
for research purposes. Results of the IGRA will not be given out nor will they be used for clinical 
decisions. 
HIV seronegative individuals with conversion of TST will be informed of this result, referred 
for exclusion of active TB, and advised to seek care in case symptoms of TB develop. 
HIV care and treatment: 
All participants will receive pretest counseling (in group for students and individual for 
health care workers) prior to being tested for HIV. All study participants will also be offered 
convenient post test counseling. All H IV testing and counseling will be provided free of charge 
and will be performed by an NGO called New Start, which has expertise and an excellent 
reputation in the field of HIV counseling and testing. Those who are found to be HIV positive will 
be referred per local guidelines for HIV care and treatment. 
Sample size, variables and analysis plan 
Sample size: 
Cohort 1: Among the HCW employed in the selected TB clinics, an estimated 50 HCWs will 
participate. These HCWs are expected to have a very high rate of L TBI (75%). An estimated 
15% of HCWs are expected to be HIV positive 59. Analysis of baseline results will allow 
estimation of prevalence of latent M. tuberculosis infection and assessment of agreement 
between TST and IGRA results (Specific Aim 4). Analysis of follow-up results will provide a 
determination of the distribution of patterns of IGRA responses over time and assessment of 
conversion and reversion rates among heavily exposed HCWs (Specific Aim 1 ). 
Cohort 2: Out of 220 eligible students an estimated 154 students will be recruited (70%). 
Analysis of baseline results will allow estimation of prevalence of latent M. tuberculosis infection 
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and assessment of agreement between TST and IGRA results (Specific Aim 2 and 4). We 
estimate that 28% of the students will have a concordantly positive TST and IGRA and will be 
excluded from the follow-up assessments 34. Analysis of follow up IGRA and TST results in the 
remaining 111 students will allow an estimation of the annual risk of MTB infection with 
adequate precision (Specific Aim 2). Assuming a 15% annual risk, the sample size will result in 
a 95% Cl of 0.08 to 0.22 for the annual risk of M. tuberculosis infection among medical students. 
An estimated 15% of students are expected to be H IV seropositive 59• 
Some have suggested that this study should be done on a larger scale to include more 
students. An increase in sample size would result in a minor increase in precision of the point 
estimate of the annual risk of infection, the outcome of interest. In the table below an increase in 
the sample from 111 to 225 is shown as an example. We intend to limit the sample size to the 
Witswatersrand medical students. 
Number of 5% Loss Infection rate ULCI LLCI Number of 5% Loss to Infection rate ULCI LLCI 
Participants toFU 
Per vear Participants FU Per vear 
111 106 10% 16 4 225 214 10% 14 06 
15% 22 8 15% 20 10 
20% 28 12 20% 25 15 
Outcome measures: 
Results of TST will be treated as a categorical variable and as a continuous measure. The 
categorical response will be defined as positive if the size of induration is ~ 5mm in HIV infected 
individuals and ~ 10 mm in HIV uninfected individuals. The continuous measure will be 
expressed as the size of induration in mm. 
Results of IGRA will also be treated as a categorical and continuous variable. The 
categorical response will be defined as positive if the response is ~ 35 IU interferon gamma, as 
per manufacturer instructions, and as negative if the response if< 35 IU interferon gamma. 
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Co variates: 
Gender: Male or Female, per self report, will be treated as a categorical variable. 
Age: Given per self report, will be treated as a continuous variable. 
Race: Will be treated as a categorical variable the local standard classifications of race are: 
White, Black, Coloured, Indian or Other. This will be defined by self report on the survey. 
Baseline HIV infection status: Will be treated as a categorical variable positive or negative 
per results of the two tests. 
End HIV status: Will be treated as a categorical variable positive or negative. 
Level of TB exposure: According to the tool developed for this study (see appendix) will be 
treated as a categorical variable. 
Survey responses: each of the questions in the survey will act as a separate covariate. 
Some will be collated according to the categories detailed in the survey. These variables will be 
treated as categorical. 
Analysis plan: 
Specific aim 1: Define the fluctuations in IGRA results among HCWs involved in direct TB care. 
We will present the IGRA results from HCWs in graphic form baseline result, by INH 
prophylaxis status and by HIV status. We will evaluate any inconsistencies with the expected 3 
patterns by comparing other variables among those individuals where IGRA pattern does not 
follow one of the 3 preconceived patterns. 
Specific aim 2: Assess the rate of IGRA and TST conversion among medical students in a high 
prevalence area for TB and HIV, and agreement between IGRA and TST conversion. 
We will calculate the incidence of latent M. tuberculosis infection during the 1-year follow 
up. Incidence will be expressed as the number conversions per person-year observation. 
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Concordance between TST and IGRA conversions will be evaluated using agreement and 
kappa statistics. We will stratify the analysis by level of exposure during the one year 
observation. Univariate and multivariate analysis will be used to identify variables independently 
associated with annual risk of infection. 
Specific aim 3: Evaluate knowledge and attitudes among HCWs and medical students towards 
TB, L TBI, and infection control measures. 
We will evaluate the knowledge and attitudes in both groups and examine if there is a 
difference within the two cohorts. 
Specific Aim 4: Estimate the prevalence of L TBI in both HCWs and medical students. 
We will calculate the prevalence of latent M. tuberculosis infection at baseline in both 
cohorts and provide a 95% confidence interval around the point estimate. Concordance 
between infection determined by TST and IGRA will be evaluated using agreement and kappa 
statistics. Univariate and multivariate analysis will be used to assess which variables are 
associated with L TBI. 
Results: 
At the time of this writing the study visits for Cohort 1 (clinic HCWs) have been delayed 
pending logistics planning and preparation in concert with our South African partners and the 
Gauteng Provincial Department of Health. Cohort 2 (medical students) have completed study 
visits 1 and 2. According to information available prior to the start of the study 220 students 
were expected to be eligible in the 3'd year medical school class. Instead there were 190 eligible 
students. Of these, only 74 (39%) participated in the study. Mean age was 23.9 years. Forty-one 
(55%} of the students were female. Twenty-four (32%) students were black, 31 (41%) white, 19 
(26%) Indian, 3 (4%) coloured, and 2 (3%) were Asian. Most (75%) grew up in an urban 
environment. Only one student had a personal history of TB. Ten students reported family with 
TB, and 22 a friend or distant relative with TB. All students' HIV tests were negative. 
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Eight students (11%) had a TST reaction greater than 15mm, 20 (27%) greater than 1 Omm, 
and 3 did not return for study visit 2 to have the test read. Twelve (17%) of the 70 students 
tested by IGRA were positive. Agreement between the IGRA and the TST with a cut off of 
1 Omm was 70% (kappa 0.1508 [95% Cl: -0.08- 0.39]). Agreement between the IGRA and the 
TST with a cut off of 15mm was 82% (kappa 0.2997 [95% Cl: 0.06-0.54]. 
The association between age, gender, race, childhood environment, and parent's 
occupation were evaluated with respect to TST interpretation or IGRA interpretation. Unadjusted 
odds ratios for each characteristic are noted in the table (Results3). None of the characteristics 
were associated with having a positive. People of black race were more likely to have a positive 
IGRA than whites (p = 0.003), and people with a rural childhood were more likely to have a 
positive IGRA than those with an urban upbringing (p = 0.006). Logistic regression was done 
with each of the variables mentioned above. Race was the only variable with a statistically 
significant (p=<0.05) coefficient. The results were tested with the likelihood ratio test. All 
variables other than race failed to add any explanatory power. 
Results 1: Medical 
Demographics Students 
(n = 75) 
Age: 23.9 (21-32) 
Gender: 
Female 41 (54.7%) 
Male 34 (45.3%) 
Race: 
Black .23 (30.7%) 
White 29 (38.7%) 
Coloured 2 ( 2.7%) 
Indian 19 (25.3%) 
Other 2 ( 2.7%) 
Childhood: 
Urban 54 (75.0%) 
Rural 9 (12.5%) 
Mixed 9 (12.5%) 
Were Parents Health Workers? 
Neither 56 (74.7%) 
Mother only 10(13.3%) 
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Father only 8 (10.7%) 
Both 1 ( 1.3%) 
TB exposure history 
None 45 (60.0%) 
A friend had TB 19 (25.3%) 
A close relative had TB 10 (13.3%) 
I have had TB 1( 1.3%) 
Results 2: Medical Students 
Visit 1 Testinq (n = 75*) 
TST (in mm) Mean 5.4 SD 7 (0-30) 
> 10 mm 20 (27.4%) 
> 15 mm 8 (11.1%) 
IGRA Adjusted Mean 0.21 SD 1.8 
(-1 0.53- 6.26) 
IGRA positive 12 (17.4%) 
HIV positive None 
• For test1ng n = 70 to 73 mdetermmate 
results not included. 
Results 3: Unadjusted Odds Ratios for IGRA results and TST results 
IGRA TST 
OR P-value 95%CI OR P-value 95%CI 
Age 1.20 0.137 0.944-1.52 0.98 0.901 0.66-1.43 
Female Sex 0.686 0.526 QJ.80-2.63 2.83 0.198 0.485-29.60 
Race 
White 1 Ref 1 ref 
Black 28.00 0.003 3.17-247.4 5.25 0.058 0.946-29.20 
Coloured 14.00 0.097 0.62-317.4 Too few 
Indian 3.29 0.345 0.28-39.14 0.78 0.842 0.066-9.217 
Other Too few Too few Too few 
Childhood environment 
Urban 1 Ref 1 ref 
Rural 14.0 0.006 2.15-91.11 0.907 0.932 0.097-8.46 
Mixed 2.33 0.352 0.39-13.91 1.16 0.894 0.122-11.2 
Parent occupation as health care worker 
Neither 1 Ref 1 ref 
Mother 1.19 0.838 0.216-6.59 2.55 0.308 0.421-15.45 
Father 2.04 0.459 0.443-9.47 2.91 0.249 0.472-17.99 
Both Too few Too few 
TB exposure history 
None 1 Ref 1 ref 
Friend 2.57 0.128 0.762-8.68 1.37 0.690 0.295-6.343 
Family Too few 1.03 0.983 0.105-9.989 
Self Too few Too few 
Data from the questionnaire are not yet available for analysis. Specific demographic information 
from the entire medical class to compare participants with non-participants is also not yet 
available. 
The main findings of the preliminary results of this study are: 1) Far fewer medical students 
chose to participate than expected (39% as compared to 70%); 2) Among those who 
participated the prevalence of HIV was zero- far less than the 15% that was expected; 3) The 
prevalence of L TBI by TST was less than expected; 4) Race and Childhood environment were 
associated with IGRA. 
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Discussion: 
In this study of medical students in Johannesburg, South Africa, a city with one of the 
highest TB incidence and HIV prevalence globally, we found that only 11% to 17.4% of medical 
students had evidence of latent tuberculosis infection when measured using TST and IGRA, 
respectively, and none of the participating medical students had a positive HIV test result. 
Prior studies on TB in health workers from low and middle income countries show very high 
average rates usually above 60% 13• 26 · 27· 62 . None of these studies specifically evaluated 
medical students but the Review by Joshi et al in 2006 presented combined numbers for 
medical and nursing students in multiple low and middle income countries. These rates were 
highly variable 7% - 40%. The only African country represented was Uganda and that was a 
40% L TBI prevalence. 
Two articles have been published since 2003 that measure HIV rates in South African health 
care workers 59' 61 . Neither of these studies included or identified medical students. Shisana et 
al. evaluated health care workers across South Africa in 2004. They used cluster methods to 
sample a representative 5% of the total health facilities in South Africa and surveyed and tested 
595 out of 721 eligible health workers identified by their sample. They presented a total HIV rate 
of 15.7% for all HCWs. They specified their findings based on professionals (Physicians and 
Nurses, n = 349) and non-professionals (n= 246). They did not specify how many of the 
professionals were physicians, and they did not test students. The HIV rate for professionals 
was 11 .7%. Shisana et al stratified HIV results by age for the full sample. HIV prevalence was 
higher at younger ages. Among 18-35 year aids HIV prevalence was 20% (n = 203), among 
36-45 year aids it was 16.6% (n=221 ). Based on this study we expected a 15% HIV prevalence 
among medical and nursing students combined. This estimate is based on the 11.7% 
prevalence for professionals and the 20% prevalence for younger health workers. 
The 0% HIV prevalence found in our study may be biased by the fact that only 39% of 
eligible students participated. In the original study design nursing students were to be included 
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along with medical students. This was changed because of practical limitations at the study site. 
It may be that there is a difference in the HIV risk of physicians as opposed to nurses or of 
students as opposed to professionals. 
A study by Connelly et al was published since we developed our protocol. They tested 1493 
out of 1813 HCWs at two hospitals in the Gauteng province of South Africa. They also stratified 
H IV prevalence by age but chose smaller intervals, 18 - 24 years, 25 - 34 years, etc. The 
overall HIV positive rate was 11.5%. For those 18-24 years old the prevalence was only 6.7% 
(n = 1 05). For 25- 35 year olds HIV prevalence was 15.9% (n = 326) The prevalence in these 
two age groups combined is 13.6%, this is lower than the 20% calculated by Shisana and may 
be more relevant for our population because it is in Gauteng Province. It also shows that the 
younger group, aged 18-24, is much less likely to be positive than the group of 18-35 year olds. 
The Connelly study also presented HIV rates for doctors, nurses, and student nurses 
separately. Physicians had a surprisingly low HIV prevalence at 2% (1 out of 49). Student 
Nurses were the professional group with the highest HIV prevalence at 13. 8% (n=65). It is 
interesting to note that while they had a response rate of 82.3% among all HCWs, among 
physicians it was less than 25%. This is consistent with our result of 39% participation and 0% 
HIV positivity. It may be that physicians and physician students are at much lower risk than 
other health workers in South Africa. It may also be that Connelly's study and ours are suffering 
from the same biased selection of only the lowest risk individuals. 
Race was correlated with positive IGRA results, with Black race being associated with 
having a positive result. Childhood background was also associated with the IGRA with people 
from rural environments more likely to have a positive IGRA. These results are all limited by the 
small numbers in this study. Other studies have shown similar results for race but usually 
children from urban environments are more likely to test positive for TB 2•4• 60 • 
In conclusion the level of participation, the prevalences of HIV and L TBI are all lower than 
expected in this sample. In order to investigate the participation- a group of medical students 
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involved in this study have started a student project to elicit reasons for participation or lack of 
participation from their peers. They hypothesize that the requirement of HIV testing is frightening 
and unacceptable for many because of the severe consequences that a positive result can 
entail in South Africa. If they are right and at-risk physicians and physician students 
systematically avoid any study that could identify HIV then it may be difficult to evaluate HIV or 
TB in this population. Others speculate that physicians in South Africa do not carry the risk of 
TB and H IV infection that other health workers do because of social separation and a distant 
approach to the practice of medicine. Regardless of the answer, for the purpose of this study 
follow up studies of HIV and TB risk for the goal of testing TB control interventions may have 
better results with nursing students and nurses as they are more likely to participate and more 
likely to suffer the highest burden of disease. 
As we move forward with the analysis and further data are collected it will be important to 
evaluate any differences between participants and non-participants to judge how well our 
sample represents the medical students. Based on our data and information from Connelly, data 
from nursing students and other health workers will need to be analyzed separately from that of 
the medical students. 
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UNC Unique patient study Identifier: 
SCHOOl. Of PUBLIC HEALTH 
TB INFECTION RISK AMONG HEALTH CARE WORKERS 
Questionnaire 
We ask you to complete this questionnaire. Please answer what you think is correct; do not ask others for their 
opinion. The questionnaire will be linked to your blood results and your tuberculin skin test. Your answers will only 
be accessible to investigators of the study and will not be shown to anyone else. Your name will never appear in any 
communication about this study. 
First, we would like to ask you some general information about yourself 
YOU MAY CHOOSE NOT TO ANSWER ANY QUESTION 
SECTION A: SOCIO-DEMOGRAPHIC INFORMATION 
Al. Age l_l_lyears 
A2. Gender D male D female 
A3. What is your ethnic or racial identity? 
D Black D White D Coloured 
D Indian D Other ____ _ 
A4. How would you describe the environment where you spent most time as child? 
D Urban (in city) D Rural D Mixed 
A5. Were your parents healthcare workers? 
D Neither D Mother only D Father only 
A6. Are you a 
D Medical student D Nursing student 
D Nurse D Laboratory worker 
A7. Do any of the scenarios below apply to you: 
0Both 
1. I have been diagnosed with TB and treated for TB D applicable D not applicable 
before. 
2. An immediate family member of mine has been D applicable D not applicable 
diagnosed with and treated for TB before 
3. Someone I know (colleague, friend or extended D applicable D not applicable 
family) has been diagnosed with and treated for 
TB before 
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SECTION B: TB KNOWLEDGE 
Now we would like to ask you questions about tuberculosis. You can either choose one answer or 
tick all answers that apply if more than one answer is correct. 
YOU MAY CHOOSE NOT TO ANSWER ANY QUESTION 
B 1. Which part of the body does TB most commonly affect? 
D Glands. D Lungs. D Bones. D Brain. 
B2. How is pulmonary TB spread? 
D Air. D Water. 0Food. 
B3. How should health workers identify TB suspects among those people attending health 
services in South Africa? 
D Take a blood sample in all people attending health services 
D Ask everyone attending if they have had a cough for more than two weeks, 
D Request a chest X-ray in all people attending health services who have been 
coughing for more than 5 days 
B4. List two safety precautions when collecting a sputum sample. 
B5. Why is a different TB treatment regimen give to previously treated patients? 
D They are more likely to have HN 
D They are more likely to have resistant TB 
D They are more likely to have side effects of the TB drugs 
B6. Compared to those not infected with HN, people living with HN are 
D Less likely to have active TB disease 
D More likely to have active TB disease 
D Equally likely to have active TB disease 
B7. Which of the following actions are effective in keeping TB from spreading to a patient's 
family and other people? 
D Close windows and doors in patient's home. 
D Open windows and doors in patient's home. 
D Tell the patient to cover his or her mouth and nose when coughing. 
D Tell the patient to eat special foods. 
D Make sure that the patient takes regular TB treatment. 
D Sterilize all dishes and other items touched by the patient. 
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B8. Which explanations below most accurately describe the presentation of latent tuberculosis 
infection? 
D People with latent tuberculosis infection present with the same symptoms as 
people with active TB disease. 
D People with latent tuberculosis infection present with different symptoms as 
people with active TB disease. 
D People with latent tuberculosis infection have no symptoms. 
B9. What may happen to people who have latent tuberculosis infection? 
D All people with latent tuberculosis infection will develop TB disease. 
D Some people with latent tuberculosis infection will develop TB disease. 
D Some people with latent tuberculosis infection will develop TB disease, 
especially those who are also infected with HIV 
B 10. How can health care workers in South Africa diagnose latent tuberculosis infection? 
D Ask person for symptoms of latent tuberculosis infection. 
D Perform chest X-ray. 
D Perform skin test. 
B 11. Can people with latent infection transmit Mycobacterium tuberculosis to others? 
D People with latent TB infection are not infectious. 
D People with latent TB infection are as infectious as people with active TB 
disease. 
D People with latent TB infection are less infectious as people with active TB 
disease. 
B 12. Which of the following is true regarding the mechanism of isoniazid preventive therapy 
(lPT)? 
D IPT prevents a person from being infected with Mycobacterium tuberculosis. 
D IPT prevents a person from developing reactivation TB disease. 
D IPT sterilizes latent TB infection 
B 13. According to South African guidelines, who should receive Isoniazid preventive therapy? 
D Health care workers in contact with adults with TB disease. 
D Everyone in contact with adults with TB disease. 
D Young children without symptoms who were in contact with an adult with TB. 
D People living with HIV who also have active TB disease 
D People living with HIV who do not have active TB 
B 14. What do you know about the effect of BCG on the tuberculin skin test? 
0No effect 
D People vaccinated with BCG are likely to have a positive skin test when they 
are not infected with tuberculosis (false positive test) 
D People vaccinated with BCG are likely to have a negative test when they are 
infected with tuberculosis (false negative test). 
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B15. What do you know about the effect ofHIV on the tuberculin skin test? 
0No effect 
D People living with HIV are likely to have a positive skin test when they are not 
infected with tuberculosis (false positive test) 
D People living with HIV are likely to have a negative test when they are 
infected with tuberculosis (false negative test). 
SECTION C: OCCUPATIONAL TB 
We would like to ask you questions about the risk of tuberculosis among health care workers. 
You can either choose one answer or tick all answers that apply if more than one answer is 
correct. 
YOU MAY CHOOSE NOT TO ANSWER ANY QUESTION 
Cl. Do you think you have been exposed to TB (at work/place of study or elsewhere) in the past 
2 months? D yes D no 
C2. How would you rate the possibility that you are infected with tuberculosis? 
D very likely D likely D unlikely D highly unlikely 
C3. How would you rate the possibility that you become infected with tuberculosis in the next 5 
years? 
D very likely D likely D unlikely D highly unlikely 
C4. How would you rate the possibility that you become ill with tuberculosis disease in the next 
5 years? 
D very likely D likely D unlikely D highly unlikely 
C5. How would you rate the possibility that you will die from tuberculosis if you were to fall ill 
with tuberculosis disease? 
D very likely D likely D unlikely D highly unlikely 
C6. Have you had training or received instructions on how to prevent becoming infected with 
tuberculosis while working in a clinic or hospital? 
Dyes Dno 
C7. Do you try to protect yourself from exposure to tuberculosis? 
Dyes Dno 
If yes, how? 
C8. If the government would offer free testing for latent tuberculosis infection using the skin test 
for all health care workers, would you agree to be tested when the skin test is used? 
Dyes If yes, why? 
4 
D no If no, why not? (check all that apply) 
0 I know it will be positive 
D I know it will be negative 
0 I don't want to know the result 
D Others might think badly of me ifl am infected 
0 It might hurt my opportunity to work if I am infected 
0 I do not believe the skin test result 
D Even if it was positive, I do not want to take 6 months of isoniazid 
0 I would only do the test for tuberculosis it ifl am infected with HIV 
D Other reason -please explain: 
C9. The government offers free testing for HIV infection for all health care workers, have you 
been tested for HIV? 
Dyes Dno 
Ifyes, why? 
If no, why not? (check all that apply) 
D 
D 
D 
D 
D 
D 
I know it will be positive 
I know it will be negative 
I don't want to know the result 
Others might think badly of me ifl am infected 
It might hurt my opportunity to work ifl am infected 
Other reason: please explain 
Cl 0. As we have explained to you, there is a new blood test for tuberculosis infection. If it is 
demonstrated that this test works better than the skin test (but is still not perfect), and the 
government would offer this blood test for free, would you want to be tested? 
Dyes Dno 
If yes, why? 
If no, why not? (check all that apply) 
D I know it will be positive 
0 I know it will be negative 
0 I don't want to know the result 
0 Others might think badly of me if I am infected 
0 It might hurt my opportunity to work if I am infected 
0 I do not believe the blood test result 
D 
D 
Even if it was positive, I do not want to take 6 months of isoniazid 
Other reason -please explain: · 
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C 11. There are several measures that can help reduce the risk of TB infection. We want your 
opinion on these measures. For each of the following possible infection control measures, please 
answer which one you think it should be done in South African clinics and hospitals? Which 
ones you think could work in South African clinics and hospitals? Which ones you think should 
be a priority? 
a. Have people who cough jump the queue by placing all those who cough at the front of 
the line, so one can quickly provide care and reduce the amount of time that others are 
exposed to them. 
Octo Onotdo 
Ocould work 
0 priority 
0 would not work 
0 not priority 
b. Hang up posters that show patients respiratory hygiene (cover mouth and nose with 
hand or tissue when coughing or sneezing) 
Octo Onotdo 
0 could work 
0 priority 
0 would not work 
0 not priority 
c. Ask all patients to wear a mask while in the clinic 
Odo Onotdo 
0 could work 
0 priority 
0 would not work 
0 not priority 
d. Ask all patients suspect of having TB to wear mask while in the clinic 
Odo Onotdo 
Ocould work 
0 priority 
0 would not work 
0 not priority 
e. Ask all patients known to have TB to wear a mask while in the clinic. 
0do Onotdo 
0 could work 
0 priority 
0 would not work 
0 not priority 
f. Ask those who cough to wait in a different area. 
Odo Onotdo 
0 could work 
0 priority 
0 would not work 
0 not priority 
g. Have all patient wait outside or in rooms with open windows, even in winter. 
Odo Onotdo 
0 could work 
0 priority 
Owould not work 
0 not priority 
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h. Always ask patients to collect their sputum sample outside 
Octo Onotdo 
Ocould work 
0 priority 
0 would not work 
0 not priority 
i. Train and educate health care workers on prevention, transmission, and symptoms of 
TB 
Octo 
0 could work 
0 priority 
Onotdo 
0 would not work 
0 not priority 
j. Start TB screening program: screening and evaluating health care workers who are at 
risk for TB disease or who might be exposed to tuberculosis. 
Octo Onotdo 
0 could work 0 would not work 
0 priority 0 not priority 
k. Have all health care workers wear a mask whenever in contact with any patient 
Odo Onotdo 
Ocould work 
0 priority 
0 would not work 
0 not priority 
1. Have all health care workers wear a mask whenever in contact with TB suspects 
Octo Onotdo 
0 could work 
0 priority 
0 would not work 
0 not priority 
m. Have all health care workers wear a mask whenever in contact with known TB 
patients 
Octo 
0 could work 
0 priority 
Onotdo 
0 would not work 
0 not priority 
n. Install UV (ultra-violet) lights in waiting rooms 
Octo Onotdo 
0 could work 
0 priority 
0 would not work 
0 not priority 
o. Install ventilation systems in clinics and hospitals (expensive) 
Octo Onotdo 
0 could work 
0 priority 
0 would not work 
0 not priority 
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If you have any comments or suggestions, feel free to write them here. 
THANKYOU VERY MUCH FOR YOUR PARTICIPATION IN THIS 
STUDY 
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